ARTICLE | Targets & Mechanisms
New targets in osteoarthritis are about more than just pain
With mechanistic insights and a nudge from FDA, companies are taking OA past analgesics into disease-modifying targets
August 23, 2019 1:09 AM UTC
New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication.
At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have moved into Phase II and III testing, and dozens of new targets are being explored in preclinical experiments and early-stage clinical trials. ...
BCIQ Company Profiles